Enoxaparin Dosing for DVT Treatment in 89.4 kg Patient
Administer enoxaparin 1 mg/kg subcutaneously every 12 hours, which equals approximately 90 mg (89.4 mg) subcutaneously twice daily for this patient.
Standard Treatment Dosing
The established therapeutic dose for DVT treatment is 1 mg/kg subcutaneously every 12 hours 1. For your 89.4 kg patient, this translates to:
- 89.4 mg (round to 90 mg) subcutaneously every 12 hours
This dosing regimen is supported by multiple high-quality guidelines including:
- ASCO Clinical Practice Guidelines (2020) 1
- NCCN Guidelines (2024) 1
- American College of Chest Physicians Guidelines (2012) 1
Alternative Once-Daily Dosing
An alternative regimen of 1.5 mg/kg once daily (approximately 134 mg daily) is also acceptable 1. However, the twice-daily regimen has more robust evidence in the DVT treatment literature and may provide more consistent anticoagulation 2, 3, 4.
Practical Dosing Considerations
Available prefilled syringes include 60 mg, 80 mg, 100 mg, 120 mg, and 150 mg formulations 5. For this 89.4 kg patient:
- Use the 80 mg syringe plus 10 mg from a 100 mg syringe (discarding 90 mg), OR
- Use the 100 mg syringe (slight overdose of ~11%, which is clinically acceptable given the therapeutic window)
The 100 mg syringe is the most practical choice, as weight-based dosing studies support enoxaparin up to 144 kg with total body weight dosing showing appropriate anti-Xa levels 1, 6.
Renal Function Assessment Critical
Before administering, verify creatinine clearance (CrCl). If CrCl <30 mL/min, reduce dosing to 1 mg/kg once daily (approximately 90 mg once daily) 1. This is essential because enoxaparin is predominantly renally cleared, and accumulation occurs in severe renal impairment 1.
Duration and Monitoring
- Continue enoxaparin for at least 5 days and until oral anticoagulation (if transitioning to warfarin) achieves therapeutic INR for 2 consecutive days 1
- For cancer-associated DVT, consider continuing LMWH monotherapy rather than transitioning to warfarin, as LMWHs show superior efficacy in this population 1
- Routine anti-Xa monitoring is not necessary for patients with normal renal function and body weight between 50-144 kg 1
Special Populations Requiring Dose Adjustment
Anti-Xa monitoring should be considered in:
- Severe renal impairment (CrCl <30 mL/min): dose reduction mandatory 1
- Extreme obesity (>144 kg): consider anti-Xa monitoring, though weight-based dosing appears safe 1, 6
- Pregnancy: monitoring may be advisable 1
Target therapeutic anti-Xa level for twice-daily dosing is 0.6-1.0 units/mL measured 4 hours post-dose 1.
Common Pitfalls to Avoid
- Do not use fondaparinux dosing (which is weight-tiered, not weight-based) 1, 7
- Do not underdose in obesity: full weight-based dosing up to 144 kg is safe and effective 1, 6
- Do not forget renal adjustment: failure to reduce dose in severe renal impairment significantly increases bleeding risk 1
- Do not use prophylactic doses (40 mg daily) for established DVT treatment 1